Prostaglandin Analog Compositions And Methods To Treat Epithelial-Related Conditions

a technology of prostaglandin and composition, applied in the field of epithelial related conditions, can solve the problems of hair loss, hair anchorage, inability to easily be pulled out, etc., and achieve the effect of restoring pigmentation to depigmented hair

Inactive Publication Date: 2009-04-30
META COSMETICS
View PDF13 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The compositions effectively stimulate hair growth and reduce intraocular pressure with minimal side effects, addressing the limitations of existing treatments for hair loss and glaucoma.

Problems solved by technology

Anagen hairs are anchored deeply into the subcutaneous fat and cannot be pulled out easily.
Those suffering from hair loss often experience embarrassment and the fear being ridiculed by others because they look different.
Loss of nasal cilia may render some more susceptible to respiratory illnesses.
Although Johnstone reported the stimulating effect of this drug on eyebrow and eyelash hair growth and pigmentation, Latanoprost works poorly on eyelashes.
Bimatoprost, which also has been found effective to increase the growth of eyelashes when applied in the FDA approved manner, dissolves best for use on eyelashes but has negative side effects, such as, for example, redness and discoloration along the periocular skin; eye irritation; and foreign body sensation.
Travaprost does not work well for eyelash growth, taking longer than other like products.
Untreated glaucoma leads to permanent damage of the optic nerve and resultant visual field loss which may progress to blindness.
The visual field loss often occurs gradually over a long period of time; damaged visual field can never be recovered.
Some forms of refractive surgery may cause traditional IOP measurements to appear normal when in fact the pressure may be abnormally high because the effect of corneal thickness and rigidity on measured values of IOP.
Such low IOP may indicate fluid leakage and deflation of the eyeball.
Each of these drugs may have local and systemic side effects.
Additionally, adherence to the drug regimen may be confusing and expensive.
Poor compliance with medications and follow-up visits is a major contributor for vision loss in glaucoma patients.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Prostaglandin Analog Compositions And Methods To Treat Epithelial-Related Conditions
  • Prostaglandin Analog Compositions And Methods To Treat Epithelial-Related Conditions
  • Prostaglandin Analog Compositions And Methods To Treat Epithelial-Related Conditions

Examples

Experimental program
Comparison scheme
Effect test

example 1

Bovine Cornea Hydrolysis Assay

[0232]The cellular effects of PGF2αin vivo are mediated by a G protein-coupled transmembrane receptor designated the FP receptor (O, Saito et al, Am J. Physiol. Renal Physiol. 284(6): F1164-70 (2003)). Woodward et. al used an isolated feline iris sphincter, where prostanoid FP receptors and prostamide receptors coexist, as a test system to show that prostaglandin-ethanolamides (prostamides) produce their effects by interacting with receptive targets distinct from prostaglandin receptors (David F. Woodward, et al., “Identification of an Antagonist That Selectively Blocks the Activity of Prostamides (Prostaglandin-Ethanolamides) in the Feline Iris,” Br. J. Pharmacol. 150(3): 352-52 (2007)).

[0233]A bovine cornea hydrolysis test system (K. M. Maxey, et al., “The Hydrolysis of Bimatoprost in Corneal Tissue Generates a Potential Prostanoid FP Receptor Agonist,” Survey of Opthalmology, 47 (Suppl 1): S34-40 (2002)) has been used to determine whether four test c...

example 2

Use for Restoring Eyelashes

[0243]In one embodiment, the composition of the present invention is a transparent gel formulated according to Table 2. The formulation comprises water, at least one prostaglandin analog according to the present invention (concentration about 0.001% to about 0.05% W / W of the composition); a thickener, optionally a hair stimulating agent; caffeine, and at least one penetrating agent and the pH adjusted to 7.2. The gel is applied as a fine line at the skin-eyelash border every night on clean dry eyes. The gel is aqueous enough to spread to the hair follicles but thick enough not to drip.

TABLE 2Transparent Gel Formulation IRange (expressedIngredientas percent by weight)Water  50-99.95Pentylene glycol 2.00-20.00Ethanol 0.1-15.00Propylene glycol alginate0.23-3.00Acrylates / C10-30 Alkyl acrylate crosspolymer0.10-1.00Butyl glycol 0.50-10.00Caffeine0.05-4.00Oleanolic Acid0.001-0.1 PPG-26-Buteth-260.001-1.0 Propylene glycol0.1-10 Apigenin0.001-0.1 Biotinoyl tripepti...

example 3

Use for Restoring Eyebrows

[0267]A composition prepared according to the present invention is formulated as a transparent gel as described in the two described embodiments of Example 2. The formulation comprises water, at least one prostaglandin analog according to the present invention (concentration about 0.001% to about 0.05% w / w of the composition); a thickener, optionally a hair stimulating agent; caffeine, and at least one penetrating agent and the pH adjusted to 7.2. The gel is applied by brush as a line at the browbone every night on clean, oil-free brows in the absence of makeup. The gel is sufficiently aqueous to spread to the hair follicles but thick enough not to drip.

[0268]Test formulations contained either 0.025% or 0.05% 16-phenoxy PGF2α cyclopropyl amide. The formulation containing 0.025% 16-phenoxy PGF2α cyclopropyl amide was used on the left side, and the formulation containing 0.05% 16-phenoxy PGF2α cyclopropyl amide was used on the right side. Test formulations we...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the formulation and delivery of prostaglandin analogs to treat epithelial-related condition. In some embodiments, the compositions of the invention are used to stimulate hair growth. In some embodiments, the compositions of the invention are used to restore hair color to depigmented hair. The present invention further relates to the formulation and delivery of prostaglandin analogs to reduce intraocular pressure.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit of U.S. Provisional Application No. 60 / 984,198, filed Oct. 31, 2007, the contents of which are incorporated by reference in their entirety.FIELD OF THE INVENTION[0002]The present invention relates to the formulation and delivery of prostaglandin analogs to treat epithelial-related conditions. In some embodiments, the compositions of the invention are used to stimulate hair growth. In some embodiments, the compositions of the invention are used to restore hair color to depigmented hair. The present invention further relates to the formulation and delivery of prostaglandin analogs to reduce intraocular pressure.BACKGROUND OF THE INVENTION[0003]Hair, a filamentous outgrowth of protein found only on mammals, is integral to our body image and can have a profound influence on our self-esteem and self-confidence. The hair of non-human mammal species is commonly referred to as fur. In some species, hair is abse...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & AuthorityApplications(United States)
IPC IPC(8): A61K31/7052A61K31/165A61K31/505A61K31/215
CPCA61K8/42A61K9/0014A61Q7/00A61K31/5575A61Q5/00A61K31/557A61P17/00A61P17/02A61P17/14A61P27/02A61P27/06A61P43/00
InventorLIPKIN, PAMELALUBIT, BEVERLY
OwnerMETA COSMETICS